Press Releases
-
August 1, 2017
Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions
(PDF)
-
June 14, 2017
Aptinyx to Present Data for NYX-2925 at the 6th International Congress on Neuropathic Pain
(PDF)
-
May 17, 2017
Aptinyx to Present NYX-2925 Research at American Pain Society Annual Scientific Meeting
(PDF)
-
February 21, 2017
Aptinyx Chief Scientific Officer Joseph Moskal, Ph.D. Named Fellow by National Academy of Inventors and the American Institute for Medical and Biological Engineering
(PDF)
-
November 14, 2016
Aptinyx to Present Data for NYX-2925 in Models of Neuropathic Pain and Traumatic Brain Injury at Neuroscience 2016
(PDF)
-
November 10, 2016
Aptinyx Awarded Up to $2.85 Million in NIH Grants to Research NMDA Receptor Modulation for the Treatment of Neuropathic Pain and Age-Related Cognitive Decline
(PDF)
-
September 13, 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
(PDF)
-
July 13, 2016
Aptinyx Initiates Dosing in Phase 1 Clinical Study of Lead NMDA-Receptor Modulator, NYX-2925
(PDF)
-
May 10, 2016
Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders
(PDF)
-
September 16, 2015
Former Naurex Team Launches New Spin-Out Company, Aptinyx
(PDF)
